A RANDOMIZED, PHASE II TRIAL OF CIRCULATING TUMOR DNA-GUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK, ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER (DARE)
Details
Age
Adult
Locations
Cherry Creek Medical Center
Highlands Ranch Hospital
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
Peter Kabos
Study ID
Protocol Number: 20-2773
More information available at ClinicalTrials.gov: NCT04567420
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers